Diabetic Retinopathy
Clinically validated detection of DR and other retinopathies from non-dilated fundus imaging.
The retina as an emerging vital sign. Detect diabetes, cardiovascular and more — in seconds, non-invasively.
Ainnova Tech is a health-tech company turning a simple retinal scan into life-saving early diagnosis.
Our AI-powered platform enables fast, accurate detection of diabetic retinopathy and other retinal diseases through a simple, non-invasive fundus eye test — with results in seconds. A scalable screening tool for primary care, pharmacies and health campaigns.
Explore the platform
Clinically validated detection of DR and other retinopathies from non-dilated fundus imaging.
AICVD predicts 10-year risk of coronary artery disease — validated with Apollo Hospitals.
ML model estimating 3-year risk of prediabetes / T2D, built on 40,000+ patient records.
Identifies likelihood of advanced fibrosis in NAFLD patients across 25 clinical parameters.
Forecasts eGFR decline in CKD stages 1–4 to optimize intervention timing.
Expanding VisionAI to AMD, glaucoma and early Alzheimer's markers from retinal imaging.
Trusted by leaders in global healthcare
Tell us about your organization and we'll show you how VisionAI brings fast, non-invasive early disease detection to your patients.
44 Louisiana St, Lyric Tower
Houston, Texas, 77002
+1 (346) 474-6572
Plaza Roble Corporate Center
Escazú, San José
+506 2201 1486
Mazaryk 111, Piso 1
Polanco, Ciudad de México
+52 55 88741865
Discover how VisionAI and our full portfolio help providers detect risks earlier and improve patient outcomes.
Request a demo